Drugs / HRS-1358
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05628870 | Feb 2023 → Jun 2025 overdue | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06679036 | Jan 2025 → Oct 2026 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06555068 | Aug 2024 → Dec 2027 expected | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07125950 | Sep 2025 → Sep 2027 expected | breast cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-1358 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06555068 ↗ |
| Route | Oral | “HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally” NCT05628870 ↗ |